


PHARMACEUTICAL 2017

Propanc Biopharma Inc. Rank 287 of 292





PHARMACEUTICAL 2017

Propanc Biopharma Inc. Rank 287 of 292

The relative strengths and weaknesses of Propanc Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Propanc Biopharma Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 501% points. The greatest weakness of Propanc Biopharma Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 608% points.

The company's Economic Capital Ratio, given in the ranking table, is -831%, being 834% points below the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	363
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,944
Liabilities, Non-Current	0
Other Assets	3.8
Other Compr. Net Income	30
Other Expenses	-48
Other Liabilities	0
Other Net Income	-2,585
Other Revenues	0
Property and Equipment	13
Research and Development	1,447
Selling, General and Administrative Expense	5,426

Output Variable	Value in 1000 USD
Assets	379
Liabilities	2,944
Expenses	6,825
Revenues	0
Stockholders Equity	-2,565
Net Income	-9,410
Comprehensive Net Income	-9,395
Economic Capital Ratio	-831%

